These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
701 related articles for article (PubMed ID: 30444904)
1. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. Lin ZP; Zhu YL; Lo YC; Moscarelli J; Xiong A; Korayem Y; Huang PH; Giri S; LoRusso P; Ratner ES PLoS One; 2018; 13(11):e0207399. PubMed ID: 30444904 [TBL] [Abstract][Full Text] [Related]
2. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Lin ZP; Ratner ES; Whicker ME; Lee Y; Sartorelli AC Mol Cancer Res; 2014 Mar; 12(3):381-393. PubMed ID: 24413181 [TBL] [Abstract][Full Text] [Related]
3. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer. Lin ZP; Al Zouabi NN; Xu ML; Bowen NE; Wu TL; Lavi ES; Huang PH; Zhu YL; Kim B; Ratner ES Sci Rep; 2021 Apr; 11(1):8042. PubMed ID: 33850183 [TBL] [Abstract][Full Text] [Related]
5. ALDH1A1 Contributes to PARP Inhibitor Resistance via Enhancing DNA Repair in BRCA2 Liu L; Cai S; Han C; Banerjee A; Wu D; Cui T; Xie G; Zhang J; Zhang X; McLaughlin E; Yin M; Backes FJ; Chakravarti A; Zheng Y; Wang QE Mol Cancer Ther; 2020 Jan; 19(1):199-210. PubMed ID: 31534014 [TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer. Hijaz M; Chhina J; Mert I; Taylor M; Dar S; Al-Wahab Z; Ali-Fehmi R; Buekers T; Munkarah AR; Rattan R Gynecol Oncol; 2016 Aug; 142(2):323-31. PubMed ID: 27282964 [TBL] [Abstract][Full Text] [Related]
7. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer. Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663 [TBL] [Abstract][Full Text] [Related]
8. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
10. Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy. Sui H; Shi C; Yan Z; Li H Drug Des Devel Ther; 2015; 9():3183-90. PubMed ID: 26124641 [TBL] [Abstract][Full Text] [Related]
11. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307 [TBL] [Abstract][Full Text] [Related]
12. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines. Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868 [TBL] [Abstract][Full Text] [Related]
13. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143 [TBL] [Abstract][Full Text] [Related]
14. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688 [TBL] [Abstract][Full Text] [Related]
15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
16. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272 [TBL] [Abstract][Full Text] [Related]
17. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812 [TBL] [Abstract][Full Text] [Related]
18. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Karakashev S; Zhu H; Yokoyama Y; Zhao B; Fatkhutdinov N; Kossenkov AV; Wilson AJ; Simpkins F; Speicher D; Khabele D; Bitler BG; Zhang R Cell Rep; 2017 Dec; 21(12):3398-3405. PubMed ID: 29262321 [TBL] [Abstract][Full Text] [Related]
19. VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status. Bizzaro F; Fuso Nerini I; Taylor MA; Anastasia A; Russo M; Damia G; Guffanti F; Guana F; Ostano P; Minoli L; Hattersley MM; Arnold S; Ramos-Montoya A; Williamson SC; Galbiati A; Urosevic J; Leo E; Cavallaro U; Ghilardi C; Barry ST; Bani MR; Giavazzi R J Hematol Oncol; 2021 Nov; 14(1):186. PubMed ID: 34742344 [TBL] [Abstract][Full Text] [Related]
20. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Santiago-O'Farrill JM; Weroha SJ; Hou X; Oberg AL; Heinzen EP; Maurer MJ; Pang L; Rask P; Amaravadi RK; Becker SE; Romero I; Rubio MJ; Matias-Guiu X; Santacana M; Llombart-Cussac A; Poveda A; Lu Z; Bast RC Cancer; 2020 Feb; 126(4):894-907. PubMed ID: 31714594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]